Mantle Cell Lymphoma Care From Diagnosis Through Relapse: Expert Guidance on Applying the Latest Evidence as Part of Clinical Routine

Download the slides from our online module to review expert guidance and recent for management of patients with MCL, including when to initiate therapy and how to select optimal treatment for individual patients.
Stephen Ansell, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.30 MB
Released: November 13, 2018

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Pharmacyclics Inc.

Related Content

Downloadable clinician resource on CLL including current treatment algorithm and select ongoing phase III clinical trials

Andrew D. Zelenetz, MD, PhD Released: September 10, 2019

Caron A. Jacobson, MD: Latest data and clinical potential for using CAR T-cells plus checkpoint inhibitors to overcome CAR T-cell–resistant DLBCL

person default Caron A. Jacobson, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 10, 2019 Expiration: September 9, 2020

Interactive online tool providing expert and guideline-based recommendations for assessing and managing adverse events associated with BTK inhibitors, from CCO

Jeremy S. Abramson, MD, MMSc Farrukh T. Awan, MD Christopher R. Flowers, MD, MS John P. Leonard, MD Julie M. Vose, MD, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 10, 2019 Expiration: September 9, 2020

From Clinical Care Options, download slides reviewing the integration of CAR T-cell therapy into community care.

person default Michael R. Bishop, MD Jae H. Park, MD Released: September 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?